Advertisement

Endocrine

, Volume 61, Issue 3, pp 422–427 | Cite as

Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection

  • Pavel Nockel
  • Amit Tirosh
  • Mustapha El Lakis
  • Apostolos Gaitanidis
  • Roxanne Merkel
  • Dhaval Patel
  • Naris Nilubol
  • Samira M. Sadowski
  • Craig Cochran
  • Phillip Gorden
  • Electron KebebewEmail author
Endocrine Surgery

Abstract

Purpose

It has been proposed that rebound hyperglycemia after resection of insulinoma indicates a biochemical cure. However, there is scant objective data in the literature on the rate and need for intervention in hyperglycemia in patients undergoing resection of insulinoma. The goal of our study was to evaluate the rate of postoperative hyperglycemia, any predisposing factors, and the need for intervention in a prospective cohort study of all patients undergoing routine glucose monitoring.

Methods

A retrospective analysis of 33 patients who had an insulinoma resected and who underwent routine postoperative monitoring of blood glucose (every hour for the first six hours then every four hours for the first 24 h) was performed. Hyperglycemia was defined as glucose greater than 180 mg/dL (10 mmol/l).

Results

Twelve patients (36%) developed hyperglycemia within 24 h (range 1–16 h). In patients with hyperglycemia, the mean maximum plasma glucose level was 221.5 mg/dL (range 97–325 mg/dL) (12.3 mmol/l), and four (33%) patients were treated with insulin. There was no significant difference in age, gender, body mass index (BMI), tumor size, biochemical profile, or surgical approach and extent of pancreatectomy between patients who developed hyperglycemia and those who did not. Pre-excision and post-excision intraoperative insulin levels were evaluated in 14 of 33 patients. The percentage decrease of the intraoperative insulin levels was not significantly different between patients who developed hyperglycemia and those who did not. All patients with postoperative hyperglycemia had normalization of their glucose levels, and none were discharged on anti-hyperglycemic agents.

Conclusions

Hyperglycemia is common after insulinoma resection, and a subset of patients require transient treatment with insulin.

Keywords

Insulinoma Pancreatic neuroendocrine tumor Hyperglycemia Surgery 

Notes

Funding

Intramural Research Program, National Cancer Institute, National Institutes of Health.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    J. Zhou, L. Enewold, A. Stojadinovic et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control. 21, 853–861 (2010). http://www.ncbi.nlm.nih.gov/pubmed/20182788CrossRefPubMedGoogle Scholar
  2. 2.
    C.W. Anderson, J.J. Bennett, Clinical presentation and diagnosis of pancreatic neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 25, 363–374 (2016). http://www.ncbi.nlm.nih.gov/pubmed/27013370CrossRefPubMedGoogle Scholar
  3. 3.
    G.W. Krampitz, J.A. Norton, Pancreatic neuroendocrine tumors. Curr. Probl. Surg. 50, 509–545 (2013). http://linkinghub.elsevier.com/retrieve/pii/S0011384013002062CrossRefPubMedGoogle Scholar
  4. 4.
    A.O. Whipple, V.K. Frantz, Adenoma of islet cells with hyperinsulinism: a review. Ann. Surg. 101, 1299–1335 (1935). http://www.ncbi.nlm.nih.gov/pubmed/17856569CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    J.M. Guettier, A. Lungu, A. Goodling, C. Cochran, P. Gorden, The role of proinsulin and insulin in the diagnosis of insulinoma: a critical evaluation of the endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 98, 4752–4758 (2013). https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2013-2182CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    B. Hirshberg, A. Livi, D.L. Bartlett et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J. Clin. Endocrinol. Metab. 85, 3222–3226 (2000). https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem.85.9.6807CrossRefPubMedGoogle Scholar
  7. 7.
    P. Chari, S.K. Pandit, R.N. Kataria, H. Singh, D.K. Baheti, J. Wig, Anaesthetic management of insulinoma. Anaesth. 32, 261–264 (1977). http://www.ncbi.nlm.nih.gov/pubmed/192099CrossRefGoogle Scholar
  8. 8.
    W.L. Chick, S. Warren, R.N. Chute, A.A. Like, V. Lauris, K.C. Kitchen, A transplantable insulinoma in the rat. Proc. Natl Acad. Sci. USA 74, 628–632 (1977). http://www.ncbi.nlm.nih.gov/pubmed/191819CrossRefPubMedGoogle Scholar
  9. 9.
    S.S. Schwartz, D.L. Horwitz, B. Zehfus, B.G. Langer, E. Kaplan, Continuous monitoring and control of plasma glucose during operation for removal of insulinomas. Surg. 85, 702–707 (1979). http://www.ncbi.nlm.nih.gov/pubmed/222000Google Scholar
  10. 10.
    H.Y. Chang, H.S. Huang, J.D. Lin, B.Y. Huang, M.J. Huang, L.B. Jeng, Insulinoma--clinical experience in ten cases. Chang. yi xue za zhi 17, 28–38 (1994). http://www.ncbi.nlm.nih.gov/pubmed/8205495Google Scholar
  11. 11.
    J.C. Yu, Continuous monitoring for blood glucose after surgery of insulinoma and the use of insulin. Zhonghua Wai Ke Za Zhi 31, 352–354 (1993). http://www.ncbi.nlm.nih.gov/pubmed/8313754PubMedGoogle Scholar
  12. 12.
    N. Schnelle, G.D. Molnar, D.O. Ferris, J.W. Rosevear, E.A. Moffitt, Circulating glucose and insulin in surgery for insulomas. JAMA 217, 1072–1078 (1971). http://www.ncbi.nlm.nih.gov/pubmed/4327740CrossRefPubMedGoogle Scholar
  13. 13.
    J.J. Muir, S.M. Endres, K. Offord, J.A. van Heerden, J.H. Tinker, Glucose management in patients undergoing operation for insulinoma removal. Anesthesiology 59, 371–375 (1983). http://www.ncbi.nlm.nih.gov/pubmed/6314850CrossRefPubMedGoogle Scholar
  14. 14.
    G.O. Tutt, A.J. Edis, F.J. Service, J.A. van Heerden, Plasma glucose monitoring during operation for insulinoma: a critical reappraisal. Surgery 88, 351–356 (1980). http://www.ncbi.nlm.nih.gov/pubmed/6251575PubMedGoogle Scholar
  15. 15.
    J. Puig la Calle, P. Clavé, G. Capella, C. Fidal, J.M. Pou, F. Lluis, Rebound hyperglycemia and peroperative normalization of insulinemia. Complet. excision Insul? Chirurgie 118, 284-8-91 (1992)Google Scholar
  16. 16.
    Y. Matsumoto, K. Tashiro, S. Ohmura, T. Kobayashi, [Lack of hyperglycemic rebound after insulinoma removal: two case reports]. Masui 46, 664–668 (1997). http://www.ncbi.nlm.nih.gov/pubmed/9185465PubMedGoogle Scholar
  17. 17.
    J. Ahn, S.E. Lee, Y.S. Choi, A.H.K. Tan, J. Kim, Y.J. Chung, Overtly manifested diabetes mellitus after resection of insulinoma. Intern. Med. 48, 2105–2107 (2009). http://www.ncbi.nlm.nih.gov/pubmed/20009401CrossRefPubMedGoogle Scholar
  18. 18.
    E. Ademoğlu, U. Ünlütürk, K. Ağbaht, A. Karabork, D. Çorapçıoğlu, Type 2 diabetes mellitus in a patient with malignant insulinoma manifesting following surgery. Diabet. Med. 29, e133–e137 (2012). http://doi.wiley.com/10.1111/j.1464-5491.2012.03603.xCrossRefPubMedGoogle Scholar
  19. 19.
    P. Nockel, B. Babic, C. Millo et al. Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. J. Clin. Endocrinol. Metab. 102, 2016–3445 (2016). http://www.ncbi.nlm.nih.gov/pubmed/27805844Google Scholar
  20. 20.
    NICE-SUGAR Study Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group and the Canadian Critical Care Trials Group, S. Finfer, D. Chittock et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study. Intensive Care Med. 41, 1037–1047 (2015). http://www.ncbi.nlm.nih.gov/pubmed/26088909CrossRefGoogle Scholar
  21. 21.
    D.G. Watson, Insulinoma: anesthetic implications. AANA J. 55, 539–543 (1987). http://www.ncbi.nlm.nih.gov/pubmed/2827425PubMedGoogle Scholar
  22. 22.
    D.R. Matthews, A.S. Rudenski, M.A. Burnett, P. Darling, R.C. Turner, The half-life of endogenous insulin and C-peptide in man assessed by somatostatin suppression. Clin. Endocrinol. 23, 71–79 (1985). http://www.ncbi.nlm.nih.gov/pubmed/2863015CrossRefGoogle Scholar
  23. 23.
    M. Toaiari, M.V. Davì, L. Dalle Carbonare et al.. Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. J. Endocrinol. Invest. 36, 753–758 (2013). http://www.ncbi.nlm.nih.gov/pubmed/23608735PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Pavel Nockel
    • 1
    • 2
  • Amit Tirosh
    • 1
    • 3
  • Mustapha El Lakis
    • 1
  • Apostolos Gaitanidis
    • 4
  • Roxanne Merkel
    • 1
  • Dhaval Patel
    • 1
  • Naris Nilubol
    • 1
  • Samira M. Sadowski
    • 5
  • Craig Cochran
    • 6
  • Phillip Gorden
    • 6
  • Electron Kebebew
    • 7
    Email author
  1. 1.Endocrine Oncology Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Presbyterian Medical GroupEndocrine SurgeryAlbuquerqueUSA
  3. 3.NET service, Sheba MC, and Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  4. 4.Second Department of SurgeryUniversity General Hospital of Alexandroupoli, Democritus University of Thrace Medical SchoolAlexandroupoliGreece
  5. 5.Thoracic and Endocrine SurgeryUniversity Hospitals of GenevaGenevaSwitzerland
  6. 6.The National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaUSA
  7. 7.Department of Surgery, Surgery and Cancer CenterStanford University School of MedicineStanfordUSA

Personalised recommendations